๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Mytomicin-C, cisplatin and fluorouracil for advanced/recurrent head and neck squamous carcinoma. A preliminary report

โœ Scribed by Cartel, G.; Lop, A.; Clocchiatti, L.; Sibau, A.; Mansutti, M.; Vigevani, E.

Book ID
123301192
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
128 KB
Volume
47
Category
Article
ISSN
0753-3322

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Cisplatin-5-fluorouracil chemotherapy fo
Cisplatin-5-fluorouracil chemotherapy for advanced inoperable squamous carcinoma of the head and neck
โœ Johnson, Jonas T. ;Mayernik, David G. ;Myers, Eugene N. ;Nolan, Teresa A. ;Schra ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Wiley (John Wiley & Sons) โš– 368 KB ๐Ÿ‘ 2 views

Patients with locally advanced, inoperable squamous cell carcinoma of the head and neck were offered three courses of cisplatin and 96-h 5-fluorouracil (5-FU) infusion. Subsequent therapy included surgery when feasible, irradiation therapy, and a maintenance program of methotrexate (MTX)-5-FU. Thirt

Paclitaxel, cisplatin, and 5-fluorouraci
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck
โœ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 73 KB ๐Ÿ‘ 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi